Zacks Investment Research
26 Mar 2026, 17:00 UTC · 30w ago
Impact · against what's priced in
Rapport Therapeutics (RAPP) receives a positive signal from a Zacks Rank upgrade to 'Buy' driven by upward earnings estimate revisions. This trend in analyst expectations typically acts as a near-term catalyst for stock price appreciation.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish
Rapport Therapeutics, Inc. (RAPP) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates.
More positive than 77% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The upgrade to a Zacks Rank #2 (Buy) is based on an upward trend in earnings estimates, which is a strong indicator of near-term buying pressure.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 89% of ticker scores this week
The company received a Zacks Rank upgrade to #2 (Buy) due to an upward trend in earnings estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
4h ago
−10.2%
Price is moving against the score
$25.93 vs $28.88 close before publication (Mar 25) · not market-adjusted
RAPP chart →
